# Onconetix, Inc.: financial statements, quarterly

ONCO · Nasdaq · CIK 1782107 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/onco.md) · [Financials](/companies/onco/financials.md) · [Filings](/companies/onco/filings.md) · [Insiders](/companies/onco/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/onco/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.7](/filings/0001213900-25-053914.md) | [0.7](/filings/0001213900-24-073545.md) | [0.4](/filings/0001213900-24-107088.md) | [0.7 d](/filings/0001213900-26-027725.md) | [0.1](/filings/0001213900-26-055483.md) | [0.1](/filings/0001213900-26-089093.md) | [0.3](/filings/0001213900-25-110142.md) | [0.3 d](/filings/0001213900-26-027725.md) | [0.0](/filings/0001213900-26-055483.md) | [0.0](/filings/0001213900-26-089093.md) |
| Cost of revenue | $m | not reported | not reported | [0.5](/filings/0001213900-25-053914.md) | [0.6](/filings/0001213900-25-076032.md) | [0.3](/filings/0001213900-25-110142.md) | [0.1 d](/filings/0001213900-26-027725.md) | [0.1](/filings/0001213900-26-055483.md) | [0.0](/filings/0001213900-26-089093.md) | [0.0](/filings/0001213900-25-110142.md) | [0.1 d](/filings/0001213900-26-027725.md) | [0.0](/filings/0001213900-26-055483.md) | [0.0](/filings/0001213900-26-089093.md) |
| Gross profit | $m | not reported | not reported | [0.2](/filings/0001213900-25-053914.md) | [0.1](/filings/0001213900-25-076032.md) | [0.1](/filings/0001213900-25-110142.md) | [0.7 d](/filings/0001213900-26-027725.md) | [0.0](/filings/0001213900-26-055483.md) | [0.1](/filings/0001213900-26-089093.md) | [0.3](/filings/0001213900-25-110142.md) | [0.2 d](/filings/0001213900-26-027725.md) | [(0.0)](/filings/0001213900-26-055483.md) | [0.0](/filings/0001213900-26-089093.md) |
| Research and development | $m | [0.2](/filings/0001213900-24-107088.md) | [(0.2) d](/filings/0001213900-25-049687.md) | [0.0](/filings/0001213900-25-053914.md) | not reported | [0.1](/filings/0001213900-24-107088.md) | [(0.0) d](/filings/0001213900-25-049687.md) | [0.0](/filings/0001213900-25-053914.md) | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [4.3](/filings/0001213900-24-107088.md) | [6.4 d](/filings/0001213900-25-049687.md) | [3.7](/filings/0001213900-25-053914.md) | [2.2](/filings/0001213900-25-076032.md) | [2.6](/filings/0001213900-25-110142.md) | [2.6 d](/filings/0001213900-26-027725.md) | [1.7](/filings/0001213900-26-055483.md) | [1.5](/filings/0001213900-26-089093.md) | [2.3](/filings/0001213900-25-110142.md) | [1.5 d](/filings/0001213900-26-027725.md) | [2.0](/filings/0001213900-26-055483.md) | [2.2](/filings/0001213900-26-089093.md) |
| Operating income | $m | [(4.5)](/filings/0001213900-24-107088.md) | [(22.0) d](/filings/0001213900-25-049687.md) | [(11.1)](/filings/0001213900-25-053914.md) | [(13.6)](/filings/0001213900-25-076032.md) | [(2.6)](/filings/0001213900-25-110142.md) | [(29.1) d](/filings/0001213900-26-027725.md) | [(12.6)](/filings/0001213900-26-055483.md) | [(1.9)](/filings/0001213900-26-089093.md) | [(2.1)](/filings/0001213900-25-110142.md) | [(1.3) d](/filings/0001213900-26-027725.md) | [(10.2)](/filings/0001213900-26-055483.md) | [(2.7)](/filings/0001213900-26-089093.md) |
| Interest expense | $m | [0.3](/filings/0001213900-23-088387.md) | [0.2 d](/filings/0001213900-24-032225.md) | [0.2](/filings/0001213900-25-053914.md) | [0.2](/filings/0001213900-25-076032.md) | [0.2](/filings/0001213900-25-110142.md) | [0.2 d](/filings/0001213900-26-027725.md) | [0.2](/filings/0001213900-26-055483.md) | [0.2](/filings/0001213900-26-089093.md) | [0.3](/filings/0001213900-25-110142.md) | [0.0 d](/filings/0001213900-26-027725.md) | [0.0](/filings/0001213900-26-055483.md) | [0.0](/filings/0001213900-26-089093.md) |
| Income tax | $m | not reported | not reported | [(0.1)](/filings/0001213900-25-053914.md) | [0.1](/filings/0001213900-25-076032.md) | [(0.1)](/filings/0001213900-25-110142.md) | [(0.9) d](/filings/0001213900-26-027725.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(5.3)](/filings/0001213900-24-107088.md) | [(22.4) d](/filings/0001213900-25-049687.md) | [(11.1)](/filings/0001213900-25-110142.md) | [(14.3)](/filings/0001213900-25-110142.md) | [(3.8)](/filings/0001213900-25-110142.md) | [(29.4) d](/filings/0001213900-26-027725.md) | [(8.5)](/filings/0001213900-26-055483.md) | [(2.4)](/filings/0001213900-26-089093.md) | [(8.8)](/filings/0001213900-25-110142.md) | [5.7 d](/filings/0001213900-26-027725.md) | [(4.2)](/filings/0001213900-26-089093.md) | [(2.9)](/filings/0001213900-26-089093.md) |
| Diluted EPS | $ per share | [(12.21)](/filings/0001213900-24-107088.md) | not reported | [(20.08)](/filings/0001213900-25-053914.md) | [(2191.59)](/filings/0001213900-25-076032.md) | [(249.08)](/filings/0001213900-25-110142.md) | not reported | [(227.25)](/filings/0001213900-26-055483.md) | [(237.91)](/filings/0001213900-26-089093.md) | [(6.25)](/filings/0001213900-25-110142.md) | not reported | [(6.71)](/filings/0001213900-26-055483.md) | [(1.28)](/filings/0001213900-26-089093.md) |
| Basic EPS | $ per share | [(12.21)](/filings/0001213900-24-107088.md) | not reported | [(20.08)](/filings/0001213900-25-053914.md) | [(2191.59)](/filings/0001213900-25-076032.md) | [(249.08)](/filings/0001213900-25-110142.md) | not reported | [(227.25)](/filings/0001213900-26-055483.md) | [(237.91)](/filings/0001213900-26-089093.md) | [(6.25)](/filings/0001213900-25-110142.md) | not reported | [(6.71)](/filings/0001213900-26-055483.md) | [(1.28)](/filings/0001213900-26-089093.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | period not labelled (2025-08-13) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.6](/filings/0001213900-24-045172.md) | [4.5](/filings/0001213900-24-045172.md) | not reported | [0.3](/filings/0001213900-24-107088.md) | [0.6](/filings/0001213900-26-027725.md) | [1.6](/filings/0001213900-25-053914.md) | [0.3](/filings/0001213900-25-076032.md) | [0.2](/filings/0001213900-25-076032.md) | [0.8](/filings/0001213900-25-110142.md) | [5.2](/filings/0001213900-26-089093.md) | [3.7](/filings/0001213900-26-055483.md) | [5.9](/filings/0001213900-26-089093.md) |
| Current assets | $m | [5.8](/filings/0001213900-25-049687.md) | [6.3](/filings/0001213900-24-045172.md) | [2.0](/filings/0001213900-24-073545.md) | [1.0](/filings/0001213900-24-107088.md) | [1.0](/filings/0001213900-26-027725.md) | [2.4](/filings/0001213900-25-053914.md) | [0.9](/filings/0001213900-25-076032.md) | not reported | [1.3](/filings/0001213900-25-110142.md) | [6.1](/filings/0001213900-26-089093.md) | [4.3](/filings/0001213900-26-055483.md) | [6.5](/filings/0001213900-26-089093.md) |
| Total assets | $m | [87.5](/filings/0001213900-25-049687.md) | [75.0](/filings/0001213900-24-045172.md) | [59.5](/filings/0001213900-24-073545.md) | [61.9](/filings/0001213900-24-107088.md) | [28.2](/filings/0001213900-26-027725.md) | [18.8](/filings/0001213900-25-053914.md) | [19.1](/filings/0001213900-25-076032.md) | not reported | [19.7](/filings/0001213900-25-110142.md) | [24.9](/filings/0001213900-26-089093.md) | [14.8](/filings/0001213900-26-055483.md) | [16.4](/filings/0001213900-26-089093.md) |
| Current liabilities | $m | [17.2](/filings/0001213900-25-049687.md) | [21.4](/filings/0001213900-24-045172.md) | [20.6](/filings/0001213900-24-073545.md) | [17.4](/filings/0001213900-24-107088.md) | [18.3](/filings/0001213900-26-027725.md) | [14.0](/filings/0001213900-25-053914.md) | [12.7](/filings/0001213900-25-076032.md) | not reported | [16.3](/filings/0001213900-25-110142.md) | [9.1](/filings/0001213900-26-089093.md) | [3.1](/filings/0001213900-26-055483.md) | [2.9](/filings/0001213900-26-089093.md) |
| Total liabilities | $m | [21.9](/filings/0001213900-25-049687.md) | [25.3](/filings/0001213900-24-045172.md) | [24.0](/filings/0001213900-24-073545.md) | [20.9](/filings/0001213900-24-107088.md) | [18.6](/filings/0001213900-26-027725.md) | [14.3](/filings/0001213900-25-053914.md) | [12.8](/filings/0001213900-25-076032.md) | not reported | [16.3](/filings/0001213900-25-110142.md) | [9.2](/filings/0001213900-26-089093.md) | [3.1](/filings/0001213900-26-055483.md) | [3.0](/filings/0001213900-26-089093.md) |
| Shareholders' equity | $m | [(5.6)](/filings/0001213900-25-049687.md) | [(21.5)](/filings/0001213900-24-045172.md) | [(35.8)](/filings/0001213900-24-073545.md) | [33.9](/filings/0001213900-24-107088.md) | [8.5](/filings/0001213900-26-055483.md) | [4.0](/filings/0001213900-26-055483.md) | [5.9](/filings/0001213900-26-089093.md) | not reported | [3.4](/filings/0001213900-25-110142.md) | [15.8](/filings/0001213900-26-089093.md) | [11.7](/filings/0001213900-26-089093.md) | [13.5](/filings/0001213900-26-089093.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,040) d](/filings/0001213900-24-107088.md) | [(4,312) d](/filings/0001213900-25-049687.md) | [(5,232)](/filings/0001213900-25-053914.md) | [(3,200) d](/filings/0001213900-25-076032.md) | [(1,147) d](/filings/0001213900-25-110142.md) | [(918) d](/filings/0001213900-26-027725.md) | [(2,000)](/filings/0001213900-26-055483.md) | [(1,410) d](/filings/0001213900-26-089093.md) | [(3,178) d](/filings/0001213900-25-110142.md) | [(3,091) d](/filings/0001213900-26-027725.md) | [(2,121)](/filings/0001213900-26-055483.md) | [(1,918) d](/filings/0001213900-26-089093.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001213900-24-107088.md) | [0.0 d](/filings/0001213900-25-049687.md) | [4.6](/filings/0001213900-25-053914.md) | [17.7 d](/filings/0001213900-25-076032.md) | [2.3 d](/filings/0001213900-25-110142.md) | [3.9 d](/filings/0001213900-26-027725.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.3](/filings/0001213900-23-088387.md) | [15.9](/filings/0001213900-24-045172.md) | [15.9](/filings/0001213900-24-073545.md) | [0.4](/filings/0001213900-24-107088.md) | [0.6](/filings/0001213900-25-053914.md) | [0.0](/filings/0001213900-25-076032.md) | [0.0](/filings/0001213900-25-110142.md) | [0.0](/filings/0001213900-26-055483.md) | [0.0](/filings/0001213900-26-089093.md) | [1.4](/filings/0001213900-25-110142.md) | [0.6](/filings/0001213900-26-055483.md) | [2.2](/filings/0001213900-26-089093.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,949,107 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-089093.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.